|Bid||1.2800 x 3000|
|Ask||1.3000 x 3000|
|Day's Range||1.2700 - 1.3000|
|52 Week Range||0.2200 - 2.9900|
|Beta (3Y Monthly)||2.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2019 - Nov 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
PTI-125 is a small molecule that targets the massive neuroinflammation and neurodegeneration observed in the Alzheimer’s brain. In conjunction with the initiation of this Phase 2b study, Cassava Sciences also reported dosing of the first two patients for this study, both of which were uneventful. This Phase 2b study is supported by a research grant award from the National Institutes of Health (NIH).
(Bloomberg) -- Neurotrope Inc. plunged as much as 82%, falling below a dollar, after a placebo worked better than the company’s experimental treatment for Alzheimer’s disease.Bryostatin-1 showed a 1.3 point improvement on a score judging patients’ mental impairment after three months of treatment while patients getting a placebo treatment had a 2.1 point improvement. The stock fell as low as 81 cents -- a record -- on heavy volume more than 35 times the daily average.“We are disappointed in the topline results from the confirmatory Phase 2 study,” the company’s Chief Executive Officer Charles Ryan said in a statement. “Having just received the data, we are conducting a full review to determine potential next steps.”One of the two analysts tracked by Bloomberg who covers Neurotrope, Maxim’s Jason McCarthy, cut his rating to hold from buy, and removed his $16 price target on the company. He said he was awaiting clarity on if there will be a path forward for bryostatin.Drug developers have been racking up failures in Alzheimer’s as they seek to find a cure for this scourge of aging. Biogen Inc.’s disappointing March results for a drug targeting beta amyloid -- a plaque that builds up in the brain of Alzheimer’s patients -- rocked the market.Drugmakers are persisting nevertheless. Biogen, Eli Lilly & Co., Roche Holding AG as well as small-cap Cassava Sciences Inc. are developing new medicines that target a pathway called tau. Cassava reported its own early results Monday morning, focused on biomarkers of the disease. Cassava’s stock fell 9.3% at 2:25 p.m. The decline could be the result of pressure from Neurotrope’s failure, McCarthy said. Or it could be due to the small size of the study, which included just 13 patients. McCarthy rates Cassava a buy.(Updates to add analyst commentary in fourth and sixth paragraphs)To contact the reporter on this story: Cristin Flanagan in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Catherine Larkin at email@example.com, Jim Silver, Divya BaljiFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. ACADIA Pharmaceuticals (NASDAQ: ACAD ) shares ...
Lead drug candidate, PTI-125, significantly decreased key biomarkers of neuroinflammation and neurodegeneration in all study patients (p
If you're interested in Cassava Sciences, Inc. (NASDAQ:SAVA), then you might want to consider its beta (a measure of...
AUSTIN, Texas, Sept. 03, 2019 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, announced today that Remi Barbier, President & CEO, will.
AUSTIN, Texas, Aug. 12, 2019 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biopharmaceutical company developing PTI-125 for Alzheimer’s disease, today reported.
Every investor in Cassava Sciences, Inc. (NASDAQ:SAVA) should be aware of the most powerful shareholder groups...
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced today that Remi Barbier, its President and CEO, will present at Maxim Group’s conference on Alzheimer’s disease on Wednesday, June 26th, in New York. Maxim’s conference for investors, titled “Alzheimer’s Disease – What’s Next? Treating Alzheimer’s in a Post-Amyloid World”, will be held at their corporate offices at 405 Lexington Ave in New York. Cassava Sciences’ presentation for this conference is now available on the Company’s website under https://www.cassavasciences.com/company-presentations.
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced today the launch of its newly designed website, www.CassavaSciences.com. Cassava Sciences’ new website has extensive information on Alzheimer’s disease, a key focus of the Company’s research and development. Cassava Sciences expects to announce results of its Phase2a study in the second half of 2019, after patient data are analyzed.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
AUSTIN, Texas, April 29, 2019 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biopharmaceutical company, today reported financial results for the first quarter ended March 31,.
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced the completion of patient enrollment in a clinical study evaluating the safety of its investigational drug, PTI-125, in patients with Alzheimer’s disease. Cassava Sciences is conducting this Phase 2a study with scientific and financial support from the National Institutes of Health (NIH).